Year archive

Orexo — 2012 filings

All 75 regulatory filings released by Orexo (ORX) in 2012, sourced directly from the official regulator.

75 Filings

2012 Period

2012 filings (75)

Filing	Released	Lang
Antal aktier och röster i Orexo Share Issue/Capital Change	2012-12-28	Swedish
Number of shares and votes in Orexo Declaration of Voting Results & Voting Rights Announcements	2012-12-28	English
Orexo provides US commercialization progress update and direction for 2013 financial outlook Earnings Release FY 2013	2012-12-19	English
Orexo uppdaterar om kommersialiseringsplaner i USA och lämnar en bedömning av finansiell utveckling för 2013 Earnings Release FY 2013	2012-12-19	Swedish
Antal aktier och röster i Orexo Declaration of Voting Results & Voting Rights Announcements	2012-11-30	Swedish
Number of shares and votes in Orexo Share Issue/Capital Change	2012-11-30	English
New study by Orexo emphasizes importance of Zubsolv™ product characteristics in direct comparison to Suboxone® Film Earnings Release FY 2012	2012-11-28	English
Orexos nya studie tydliggör betydelsen av produktegenskaper hos Zubsolv™ jämfört med Suboxone® Film Regulatory Filings	2012-11-28	Swedish
Orexo meddelar att Zubsolv™ nu accepterats för granskning av den amerikanska läkemedelsmyndigheten (FDA) Earnings Release FY 2013	2012-11-19	Swedish
Orexo announces that Zubsolv™ has been accepted for review by the U.S. Food and Drug Administration (FDA) Regulatory Filings	2012-11-19	English
Orexo announces submission of a New Drug Application for KW-2246 (Abstral®) in Japan Regulatory Filings	2012-11-13	English
Orexo meddelar att en registreringsansökan för KW-2246 (Abstral®) lämnats in i Japan Regulatory Filings	2012-11-13	Swedish
Antal aktier och röster i Orexo Declaration of Voting Results & Voting Rights Announcements	2012-10-31	Swedish
Number of shares and votes in Orexo Declaration of Voting Results & Voting Rights Announcements	2012-10-31	English
Orexo announces dosing of first patient with OX51 in phase II clinical trial on prevention of procedure-induced pain Regulatory Filings	2012-10-30	English
Orexo meddelar dosering av första patienten med OX51 i en klinisk fas II studie för förebyggande av procedurinducerad smärta Legal Proceedings Report	2012-10-30	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-10-25	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-10-25	English
Orexo utser valberedning och offentliggör finansiell kalender 2012/2013 Report Publication Announcement	2012-10-11	Swedish
Orexo appoints Nomination Committee and publishes financial calendar 2012/2013 Report Publication Announcement	2012-10-11	English
Orexo announces decision to explore strategic alternatives for commercialization in the US M&A Activity	2012-10-04	English
Orexo utvärderar strategiska alternativ för kommersialisering i USA Regulatory Filings	2012-10-04	Swedish
Number of shares and votes in Orexo Share Issue/Capital Change	2012-09-28	English
Antal aktier och röster i Orexo Declaration of Voting Results & Voting Rights Announcements	2012-09-28	Swedish
Orexo ger en uppdatering kring det förändrade marknadsläget för Zubsolv™ (OX219) i USA Regulatory Filings	2012-09-25	Swedish
Orexo provides update on simplified market situation for Zubsolv™ (OX219) in United States Legal Proceedings Report	2012-09-25	English
Orexo presents an update on the US opioid dependence market, and the commercial opportunities for Zubsolv™ (OX219) Regulatory Filings	2012-09-21	English
Orexo ger en uppdatering om den amerikanska marknaden för opiatberoende och möjligheter till kommersialisering av Zubsolv™ (OX219) Earnings Release FY 2012	2012-09-21	Swedish
Orexo invites to a Zubsolv™ (OX219) information meeting on September 21 in Stockholm Report Publication Announcement	2012-09-17	English
Orexo bjuder in till Informationsträff kring Zubsolv™ (OX219) den 21 september 2012 i Stockholm Regulatory Filings	2012-09-17	Swedish
Swedish specialty pharmaceutical company Orexo announced today the submission of a New Drug Application for Zubsolv™ (OX219) to the US FDA Regulatory Filings	2012-09-06	English
Orexo bekräftar idag inlämningen av en registreringsansökan till den amerikanska läkemedelsmyndigheten (”FDA”) avseende Zubsolv™ (OX219) Regulatory Filings	2012-09-06	Swedish
Orexo reports successful achievement of product stability data for OX219 – submission of the US file now advanced 5 months to September 2012 Regulatory Filings	2012-08-21	English
Orexo erhåller stabilitetsdata för OX219 – Registreringsansökan i USA tidigareläggs med fem månader till september 2012 Earnings Release Q3 2012	2012-08-21	Swedish
Orexo reports positive feedback from pre-NDA meeting with FDA – clearing path for regulatory submission of OX219 Regulatory Filings	2012-07-23	English
Orexo rapporterar om positiv feedback från pre-NDA möte med FDA – banar väg för inlämnande av ansökan för OX219 Regulatory Filings	2012-07-23	Swedish
Buyback of company shares Transaction in Own Shares	2012-07-16	English
Återköp av egna aktier Transaction in Own Shares	2012-07-16	Swedish
Report from the extraordinary general meeting in Orexo AB, 13 July 2012 AGM Information	2012-07-13	English
Kommuniké från extra bolagsstämma i Orexo AB den 13 juli 2012 Share Issue/Capital Change	2012-07-13	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report H1 2012	2012-07-12	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report H1 2012	2012-07-12	English
Orexo tar ett stort kliv framåt i arbetet att hjälpa personer beroende av smärtstillande opioidläkemedel Regulatory Filings	2012-07-02	Swedish
Orexo takes large step forward on the road to improve treatment for people dependent on opioid pain killers Legal Proceedings Report	2012-07-02	English
Antal aktier och röster i Orexo Share Issue/Capital Change	2012-06-29	Swedish
Number of shares and votes in Orexo Share Issue/Capital Change	2012-06-29	English
Orexo successfully completes OX219 dose proportionality study ahead of schedule Regulatory Filings	2012-06-19	English
Orexos OX219 dosproportionalitetstudie framgångsrikt slutfört snabbare än planerat Regulatory Filings	2012-06-19	Swedish
Orexo rapporterar att Edluar® är godkänd för registrering i Europa Regulatory Filings	2012-06-18	Swedish
Orexo reports regulatory approval of Edluar® in Europe Regulatory Filings	2012-06-18	English
Kallelse till extra bolagsstämma i Orexo AGM Information	2012-06-14	Swedish
Notice of Extraordinary General Meeting of Orexo AGM Information	2012-06-14	English
Orexo acquires all US rights for Abstral and receives a net cash consideration of MSEK 610 Regulatory Filings	2012-06-04	English
Orexo förvärvar samtliga USA-rättigheter för Abstral och erhåller 610 MSEK Regulatory Filings	2012-06-04	Swedish
Abstral EU success continues. Orexo receives sales milestone of 3.3 MEUR. Earnings Release Q1 2012	2012-05-25	English
Abstrals framgångar i EU fortsätter. Orexo får delmålsbetalning på 3,3 MEUR. Regulatory Filings	2012-05-25	Swedish
Orexo presents new focus and plans for commercial expansion – accelerated development of OX219 Investor Presentation	2012-05-03	English
Orexo presenterar nytt fokus och nya planer för kommersiell expansion – accelererar utvecklingen av OX219 Regulatory Filings	2012-05-03	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-27	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-27	English
Reminder: Invitation to Capital Markets Day 2012 Regulatory Filings	2012-04-26	English
Påminnelse: Inbjudan till Kapitalmarknadsdag 2012 Regulatory Filings	2012-04-26	Swedish
Kommuniké från Orexo AB:s årsstämma den 11 april 2012 AGM Information	2012-04-11	Swedish
Report from Orexo AB’s Annual General Meeting, 11 April 2012 AGM Information	2012-04-11	English
Invitation Capital Markets Day May 3, 2012 Report Publication Announcement	2012-04-04	English
Inbjudan till Kapitalmarknadsdag 3 maj 2012 Regulatory Filings	2012-04-04	Swedish
Annual Report 2011 Annual Report FY 2011	2012-03-21	Swedish
Notice of Annual General Meeting of Orexo AGM Information	2012-03-12	English
Kallelse till årsstämma i Orexo AGM Information	2012-03-12	Swedish
Orexo AB focuses its business and reduces costs Management Reports	2012-03-06	English
Orexo AB fokuserar verksamheten och minskar kostnaderna Board/Management Information	2012-03-06	Swedish
Interim / Quarterly Report 2011 Interim / Quarterly Report FY 2011	2012-01-31	Swedish
Interim / Quarterly Report 2011 Interim / Quarterly Report FY 2011	2012-01-31	English
Orexos forskningssamarbete avslutas och OX-CLI-/ OX-ESI-projekten läggs ned Legal Proceedings Report	2012-01-31	Swedish
Orexo’s drug discovery collaboration terminated and OX-CLI/OX-ESI projects end Regulatory Filings	2012-01-31	English

Filings by year

2026 10 filings
2025 26 filings
2024 27 filings
2023 24 filings
2022 16 filings
2021 25 filings
2020 33 filings
2019 30 filings
2018 32 filings
2017 28 filings
2016 45 filings
2015 65 filings
2014 64 filings
2013 75 filings
2012 75 filings
2011 65 filings
2010 60 filings
2009 49 filings
2008 53 filings
2007 41 filings